DeepCure, Google and CWX Demonstrate the Potential For Chemistry LLMs To Increase Productivity In Medicinal Chemistry

March 04, 2025 01:15 AM AEDT | By EIN Presswire
 DeepCure, Google and CWX Demonstrate the Potential For Chemistry LLMs To Increase Productivity In Medicinal Chemistry
Image source: EIN Presswire
BOSTON, MA, UNITED STATES, March 3, 2025 /EINPresswire.com/ -- DeepCure, a therapeutics company using AI to discover novel drugs for immune and inflammatory diseases, announced today the successful completion of a pilot program with Google Cloud Platform (GCP) and CloudWerx (CWX) to build an AI-driven workflow that can extract chemical insights from unstructured literature to answer complex queries on organic chemistry.

DeepCure specializes in discovering innovative small molecule therapies for undrugged protein targets to transform the lives of patients with autoimmune and inflammatory diseases. DeepCure’s MolGen™ system uses AI to design molecules that can bind to proteins that have historically been very challenging to drug. Each AI design is supported by physics-based analyses, such as molecular dynamic simulations and quantum mechanical calculations.
Chemists often require up-to-date, open-access data to complement internally generated datasets for drug design. However, this data is often in publications as unstructured text or images, which requires scientists to spend hours manually reading and documenting the information. There is a pressing need for a workflow to capture specific data from recent documents in response to queries and then structure the data so it is easily interpretable to scientists and AI tools.

DeepCure, CWX and GCP created a workflow that uses a fine-tuned LLM model trained with data extracted from public chemistry literature and a set of data harmonization instructions from DeepCure, and the output is in a format that is both understandable to chemists and directly interpretable by robotic systems. The workflow increased researcher productivity seven-fold, and additional optimization of the system could further increase productivity by an order of magnitude.

"Our new Google Cloud-based solution streamlined our chemical data harmonization process. What used to take hours of manual work now takes just minutes. We've seen over a seven-fold reduction in data processing time. This frees up our scientists to focus on complex, high-value activities such as problem-solving and more creative aspects of drug design," Thras Karydis, Chief Technology Officer and Co-Founder, DeepCure.

Google Cloud has expressed excitement about DeepCure’s use of the Google cloud-based architecture built by CWX to expand the applications of AI tools into R&D and explore new types of reasoning, and believe this will be a new frontier in innovation for many industries.

“CWX is proud to have supported DeepCure in bringing this vision to life with custom model development that parses dense scientific papers, extracts insights and chemical notations using custom LLMs and enables the DeepCure science team to accelerate discovery” said Sidhant Gupta, Chief Technology Officer, CWX. “We’ve demonstrated how quickly and effectively powerful AI tools can be deployed to augment scientists’ ability to gather and process data.”

The partnership demonstrates the potential value of using Google Cloud tools like BigQuery and VertexAI to process and analyze large volumes of data from public scientific literature, including extracting key chemical reaction details such as reactants, conditions, and molecular structures. This streamlined pipeline efficiently organizes the data for future scalability, supporting DeepCure's internal drug discovery efforts. Google's expertise in real-time patent searches, publications, images, and language translation, combined with its custom Gemini AI chatbot created by CWX, enables scientists to interact with AI and receive reasoned, data-backed responses.

###

About DeepCure
DeepCure is a therapeutics company focused on advancing novel drugs with the potential to transform the treatment of inflammation and autoimmune diseases. The company was founded by researchers at MIT to accelerate breakthrough therapies using artificial intelligence (AI) and AI-enabling technologies for small molecule drug discovery. The company is based in Boston, MA, and its engineers, chemists, and biologists collaborate to find solutions to hard problems that will have an enormous impact on patient health. For more information, visit www.deepcure.ai.

About CWX
CWX is a Google Cloud solutions provider built with a global force of engineering experts, laser-focused on conquering your toughest challenges. With a team of elite tech talent and an unwavering commitment to next-level customer service, they empower businesses to accelerate and thrive in even the most complex Google Cloud environments. As a Google Cloud Premier Partner, the 2023 North American Sales Partner of the Year, and the recipient of Google Cloud's 2024 North American Breakthrough Partner of the Year, they are not just keeping pace with cloud innovation—they are setting the pace. Ready to break boundaries and achieve the impossible? For more information, visit https://www.cwx.tech/.

About Google Cloud
Google Cloud is the new way to the cloud, providing AI, infrastructure, developer, data, security, and collaboration tools built for today and tomorrow. Google Cloud offers a powerful, fully integrated and optimized AI stack with its own planet-scale infrastructure, custom-built chips, generative AI models and development platform, as well as AI-powered applications, to help organizations transform. Customers in more than 200 countries and territories turn to Google Cloud as their trusted technology partner.

Nicolia Wiles
PRIME|PR
+1 512-698-7373
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.